PTEN immunohistochemical expression is suppressed in G1 endometrioid adenocarcinoma of the uterine corpus
- 187 Downloads
PTEN is a tumor suppressor gene that inhibits cell proliferation by regulating intracellular signaling pathways, and this activity can be abolished by mutations of the PTEN gene. This study was designed to examine the correlation of PTEN expression with the expression of cell cycle regulators and with clinicopathological parameters in endometrioid adenocarcinoma of the uterine corpus.
Tissue samples of 117 endometrioid adenocarcinomas in addition to those of 19 normal endometria and 20 endometrial hyperplasias were used for the study. Immunohistochemical staining for PTEN protein was performed with the labeled streptavidin-biotin method on formalin-fixed and paraffin-embedded tissue samples. PTEN expression was represented as the staining score.
Immunohistochemistry showed that the nuclei of cells were positive for PTEN. The PTEN staining score of normal endometrium was significantly higher in the proliferative phase than in the secretory phase. The scores of various endometrial hyperplasias were not significantly different from each other, regardless of the type of hyperplasia. The PTEN staining scores of endometrioid adenocarcinomas were 7.6±5.2 in G1, 9.6±5.2 in G2, and 11.9±3.7 in G3, and increased significantly as the histological grade increased. PTEN staining score was not significantly correlated with clinicopathological parameters such as FIGO stage, myometrial invasion, lymph-vascular space invasion (LVSI), lymph node metastasis or group, but was significantly correlated with labeling indices (LIs) of cell cycle regulators such as Ki-67, cdk2, cyclin A, cyclin D1, cyclin E, p27, and p53. The PTEN staining score of p53-wild cases was significantly lower than that of p53-mutant ones, but there was no significant difference of the score in cases with different PTEN gene status. PTEN expression was significantly lower in cases with both high levels of estrogen receptor and progesterone receptor.
PTEN protein expression was decreased in well-differentiated and less growth-aggressive endometrial carcinoma with wild-type p53 gene and high levels of ER and PR. This suggests that disturbed PTEN expression occurs in an early phase of the tumorigenesis of well-differentiated endometrial carcinoma.
KeywordsPTEN p53 Estrogen receptor Progesterone receptor Endometrioid adenocarcinoma
This work was supported by grants-in-aid for the Project Research of Graduate School of Medical Sciences, Kitasato University (Grants 2005 and 4007) and for Scientific Research from the Ministry of Education, Culture, Sports, Sciences, and Technology (Grants 12670176 and 12671627), Japan
- Fujisawa T, Watanabe J, Akaboshi M, Ohno E, Kuramoto H (2001) Immunohistochemical study on VEGF expression in endometrial carcinoma – comparison with p53 expression, angiogenesis, and tumor histologic grade. J Cancer Res Clin Oncol 127:668–674Google Scholar
- Gimm O, Perren A, Weng L-P, Marsh DJ, Yeh JJ, Ziebold U, Gil E, Hinze R, Delbridge L, Lees JA, Mutter GL, Robinson BG, Komminoth P, Dralle H, Eng C (2000) Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and benign and malignant epithelial thyroid tumors. Am J Pathol 156:1693–1700Google Scholar
- Hinoda Y, Idogawa M, Imai K (1998) Involvement of protein tyrosine phosphatases in cancer development. Protein Nucleic Acid Enzyme 43:1186–1192Google Scholar
- Maehama T, Dixon JE (2000) Function of PTEN as a phospholipid phosphatase. Cell Technol 19:751–753Google Scholar
- Mochizuki Y (1999) Tumor suppressor gene PTEN/MMAC1 is lipid phosphatase. Exp Med 17:1195–1199Google Scholar
- Ohkawara S, Jobo T, Sato R, Kuramoto H (2000) Comparison of endometrial carcinoma coexisting with and without endometrial hyperplasia. Eur J Gynaec Oncol 6:573–577Google Scholar
- Ohtani K, Sakamoto H, Satoh K (1999) Molecular pathogenesis of endometrial hyperplasia and adenocarcinoma. Nihon Univ J Med 41:181–193Google Scholar
- Steck PA, Pershouse MA, Jasser SA, Yung WKA, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T, Frye C, Hu R, Swedlund B, Teng DHF, Tavtigian SV (1997) Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nature Genet 15:356–362PubMedGoogle Scholar
- Tamura M, Gu J, Yamada KM (1998a) Tumor suppressor PTEN: a negative regulator of cell adhesions via integrins. Exp Med 16:2211–2213Google Scholar
- Watanabe J, Sato H, Kanai T, Kamata, Y, Jobo T, Hata H, Fujisawa T, Ohno E, Kuramoto H (2002) Paradoxical expression of cell cycle inhibitor p27 in endometrioid adenocarcinoma of the uterine corpus — correlation with proliferation and clinicopathological parameters. Br J Cancer 87:81–85Google Scholar
- Watanabe J, Kamata Y, Kanai T, Seo N, Fujisawa T, Nishimura Y, Hamano M, Jobo T, Kuramoto H (2003) Expression of cell cycle regulators in endometrial adenocarcinoma. Kuramoto H, Nishida M (eds) Cell and molecular biology of endometrial carcinoma. Springer, Tokyo, pp 93–106Google Scholar